Paul Mattels

Stock Analyst at Stifel

(n/a)
# 4,373
Out of 4,734 analysts
4
Total ratings
n/a
Success rate
-24.56%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Paul Mattels

Denali Therapeutics
Dec 16, 2024
Upgrades: Buy
Price Target: $37
Current: $21.93
Upside: +68.72%
Alector
Feb 19, 2020
Initiates: Buy
Price Target: $44
Current: $1.71
Upside: +2,473.10%